Printer Friendly

Nanogen issued patent for technology enabling assay development to detect difficult nucleic acid sequences.

Nanogen, Inc. (San Diego, CA) developer of advanced diagnostic products, announced that its subsidiary, Epoch Biosciences, was issued Patent 6,962,991, "Process for the synthesis of pyrazolopyrimidines" by the United States Patent and Trademark Office. The '991 patent relates to a process for the synthesis of pyrazolopyrimidine nucleoside phosphoramidites. This process allows the economical production of these important nucleic acid building components. The incorporation of pyrazolopyrimidine bases into nucleic acid probes and primers in place of the normal guanine (G) base allows the development of diagnostic assay reagents that can target sequences intractable to normal probes and primers.

Efficient and accurate detection of nucleic acid targets play an integral role in infectious and genetic disease management. Under normal circumstances, nucleic acid sequences that have large stretches of G residues have a tendency to bind together instead of binding to their complementary DNA strand, making those sequences extremely difficult to design assays to detect. Use of pyrazolopyrimidine-modified oligonucleotides can eliminate self-association in primers and probes with high GC-content. This technology allows Nanogen to develop highly sensitive amplification-based diagnostic assays, solving a serious limitation in the traditional design of assays. Often times these intractable sequences can code for genes altered by mutations or changed by diseases such as cancer, so detection of molecular events can be critical in managing patient treatment.

"Nanogen's technologies for molecular diagnostics uniquely position us to develop assays for diseases that cannot be detected by other nucleic-acid based technologies," noted Howard C. Birndorf, chairman and chief executive officer of Nanogen. "This intellectual property distinguishes the real-time PCR analyte specific reagents we're developing for these unmet needs in diagnostics, which we'll use to secure a solid position in the rapidly growing molecular testing market."

Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip electronic microarray platform and a line of rapid diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biowarfare applications.

Nanogen, Inc.

COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Epoch Biosciences Inc.
Comment:Nanogen issued patent for technology enabling assay development to detect difficult nucleic acid sequences.(Epoch Biosciences Inc.)
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Nov 1, 2005
Previous Article:Clarient and Health Discovery Corporation announce bioinformatics patent licensing agreement.
Next Article:Defenders of property rights optimistic Brazil is backing away from United States AIDS drug patent threat.

Related Articles
Promega receives genomics patent for innovative Snp scoring method.
Nanogen awarded United States patent on method for detecting nucleic acid hybridization by means of fluorescent energy transfer.
Ribozyme broadens patent portfolio with DNAzyme rights.
University of Utah awarded United States patent for use of dye in PCR.
Affymetrix announces expanded genomic technologies licensing program.
Nanogen issued patent for device that combines optical waveguides and molecular diagnostics.
Human Genome Sciences obtains United States patent.
Nanogen issued patent for ligation-based strand displacement amplification.
Nanogen announces patent for fluorescent detection of nucleic acid targets.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |